Latest market price
8.44
+0.14+1.69%
Earnings
Up 1.7% — Earnings due 2026-11-05 — pre-report positioning.
Medium confidence
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -0.76 | Insider Own | 10.33% | Shs Outstand | 83.65M | Perf Week | 0.60% |
| Market Cap | 705.97M | Forward P/E | 4.23 | EPS next Y | 2.00 | Insider Trans | 0.00% | Shs Float | 81.33M | Perf Month | -8.86% |
| Enterprise Value | 13.71B | PEG | — | EPS next Q | 0.47 | Short Float | 4.02% | Perf Quarter | -33.33% | ||
| Income | 0.00 | P/S | 1.04 | EPS this Y | 7.02% | Short Ratio | 2.95 | Perf Half Y | -38.08% | ||
| Sales | 677.00M | P/B | 0.29 | EPS next Y | 5.18% | ROA | 0.01% | Short Interest | 3.27M | Perf YTD | -32.10% |
| Book/sh | 28.88 | P/C | 1.59 | EPS next 5Y | 0.09% | ROE | 0.05% | 52W High | 14.18 -40.48% | Perf Year | -33.02% |
| Cash/sh | 5.31 | P/FCF | — | EPS past 3/5Y | — 67.27% | ROIC | -1.07% | 52W Low | 8.11 4.07% | Perf 3Y | -39.24% |
| Dividend Est. | 1.80 (21.33%) | EV/EBITDA | 80.66 | Sales past 3/5Y | — 29.43% | Gross Margin | 52.06% | Volatility | 2.35% 2.79% | Perf 5Y | -82.01% |
| Dividend TTM | 1.72 (20.38%) | EV/Sales | 20.25 | EPS Y/Y TTM | -159.68% | Oper. Margin | 21.83% | ATR (14) | 0.26 | Perf 10Y | -81.73% |
| Dividend Ex-Date | Sep 30, 2026 | Quick Ratio | 3.10 | Sales Y/Y TTM | 62.74% | Profit Margin | 0.18% | RSI (14) | 34.99 | Recom | 3.06 |
| Dividend Gr. 3/5Y | -23.91% -18.83% | Current Ratio | 3.10 | EPS Q/Q | 17.95% | SMA20 | -1.30% | Beta | 1.82 | Target Price | 10.75 |
| Payout | — | Debt/Eq | 5.57 | Sales Q/Q | 68.33% | SMA50 | -15.20% | Rel Volume | 0.89 | Prev Close | 8.30 |
| Employees | 423 | LT Debt/Eq | 5.57 | Earnings | Nov 05 | SMA200 | -31.27% | Avg Volume | 1.25M | Price | 8.44 |
| IPO Date | Nov 29, 2007 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -14.42% — | Net Debt/EBITDA | 76.51 | Volume | 1,114,750 | Change | 1.69% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Dec-09-25 | Reiterated | RBC Capital | Outperform | $13 |
| Nov-18-25 | Reiterated | UBS | Buy | $16 |
| May-14-25 | Upgrade | UBS | Neutral → Buy | |
| Jun-23-23 | Reiterated | Credit Suisse | Neutral | $5.50 |
| Apr-27-22 | Reiterated | Barclays | Underweight | $11 |
| Dec-10-20 | Downgrade | Barclays | Equal Weight → Underweight | |
| Aug-21-19 | Downgrade | Credit Suisse | Outperform → Neutral | |
| Feb-14-19 | Downgrade | Deutsche Bank | Buy → Hold | |
| Oct-24-18 | Upgrade | Deutsche Bank | Hold → Buy | |
| Aug-02-18 | Downgrade | Deutsche Bank | Buy → Hold |
Latest News· Times ET
Oct-30-26
Oct-30-2612:00PM
Oct-22-26
Oct-22-2604:30PM
Oct-12-26
Oct-12-2611:02AM
Oct-09-26
Oct-05-26
Oct-02-26
Oct-01-26
Oct-01-2604:08PM
Sep-29-26
Sep-29-2603:39AM
Sep-18-26
Sep-17-26
Sep-17-2604:30PM
Sep-15-26
Sep-15-2610:40AM
Sep-04-26
Aug-28-26
07:17AM
Aug-21-26
Aug-21-2601:13PM
Company
Chimera Investment Corporation (CIM) operates as a U.S.-based real estate investment trust (REIT), having elected to be taxed under this specific structure. Through its various subsidiaries, the company primarily focuses on building a diverse portfolio of mortgage-related assets. This encompasses holdings such as residential mortgage loans, both agency-backed and non-agency residential mortgage-backed securities (RMBS), and agency mortgage-backed securities (MBS) that are collateralized by pools of both residential and commercial mortgage loans. Additionally, CIM invests in other financial instruments tied to the real estate sector. Its investment scope further extends to include securities across the credit spectrum, ranging from investment-grade and non-investment-grade classes to non-rated tranches. The firm was established in 2007 and is headquartered in New York, New York.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 677 | 821 | 258 | 205 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 325 | 42 | 0 | 0 | — | — | — | — | — | |
| Gross Profit | 352 | 779 | 258 | 205 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 80 | 30 | 65 | 56 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | 125 | -16 | 193 | 149 | — | — | — | — | — | |
| Operating Income | 148 | 765 | 0 | 0 | — | — | — | — | — | |
| Interest Expense | 593 | 555 | 496 | 510 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 444 | 23 | 672 | 636 | — | — | — | — | — | |
| Net Income Before Taxes | -1 | 233 | 176 | 126 | — | — | — | — | — | |
| Income Taxes | -2 | 2 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | 0 | 230 | 176 | 126 | — | — | — | — | — | |
| Net Income From Continuing Operations | 0 | 230 | 176 | 126 | — | — | — | — | — | |
| Net Income | 0 | 230 | 176 | 126 | — | — | — | — | — | |
| EPS (Recurring) | -0.75 | 2.80 | 1.12 | 0.55 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.75 | 2.80 | 1.12 | 0.55 | — | — | — | — | — | |
| EPS (Diluted) | -0.76 | 2.75 | 1.10 | 0.54 | — | — | — | — | — | |
| EBITDA | 170 | 795 | 673 | 636 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | 4.52 | 12.73 | 27.72 | — | — | — | — | — | |
| Price To Sales Ratio | 1.05 | 1.24 | 4.40 | 5.62 | — | — | — | — | — | |
| Gross Margin | 51.99 | 94.88 | 100.00 | 100.00 | — | — | — | — | — | |
| Operating Margin | 21.86 | 93.18 | 0.00 | 0.00 | — | — | — | — | — | |
| Net Margin | 0.00 | 28.01 | 68.22 | 61.46 | — | — | — | — | — | |
| Shares Outstanding | 84 | 82 | 81 | 77 | — | — | — | — | — | |
| Market Capitalization | 709 | 1,019 | 1,134 | 1,153 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| CREAGH GERARD | Director | Mar 11 '25 | Buy | 13.31 | 12,500 | 166,375 | 138,127 | Mar 13 |
| Macdowell Jack Lee Jr | Chief Investment Officer | Dec 10 '24 | Buy | 15.13 | 66,000 | 998,580 | 166,000 | Dec 12 |
| Macdowell Jack Lee Jr | Chief Investment Officer | Dec 09 '24 | Buy | 14.91 | 50,000 | 745,500 | 100,000 | Dec 09 |
| Macdowell Jack Lee Jr | Chief Investment Officer | Dec 06 '24 | Buy | 14.70 | 50,000 | 735,000 | 50,000 | Dec 09 |
| CREAGH GERARD | Director | Jun 17 '24 | Buy | 13.07 | 10,000 | 130,700 | 125,899 | Jun 18 |
| Kortman Kelley | Principal Accounting Officer | Aug 25 '21 | Buy | 26.26 | 300 | 7,878 | 5,800 | Aug 25 |
| LAMBIASE MATTHEW | CEO, President and Director | Mar 18 '20 | Buy | 8.51 | 100,000 | 851,000 | 993,876 | Mar 24 |
| DONLIN PAUL | Director | Mar 18 '20 | Buy | 7.86 | 103,483 | 813,503 | 320,609 | Mar 19 |
| CREAGH GERARD | Director | Mar 18 '20 | Buy | 8.44 | 36,000 | 303,840 | 153,637 | Mar 19 |
| Reilly Brian Patrick | Director | Mar 18 '20 | Buy | 7.49 | 5,000 | 37,450 | 22,568 | Mar 19 |
| Kardis Phillip John II | Chief Legal Officer | Mar 18 '20 | Buy | 8.11 | 3,000 | 24,330 | 186,514 | Mar 19 |
| Yarlagadda Choudhary | Chief Operating Officer | Mar 18 '20 | Buy | 7.50 | 40,900 | 306,570 | 554,288 | Mar 19 |
| COLLIGAN ROBERT S | Chief Financial Officer | Mar 18 '20 | Buy | 9.31 | 15,000 | 139,650 | 236,977 | Mar 19 |
| MARRIA MOHIT | Chief Investment Officer | Mar 18 '20 | Buy | 8.36 | 35,250 | 294,594 | 390,868 | Mar 19 |
| DONLIN PAUL | Director | Mar 16 '20 | Buy | 19.06 | 13,796 | 262,914 | 12,081 | Mar 19 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.